Categories: News

EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of February 28, 2023

Disclosure of Share Capital and Voting Rights Outstanding
as of February 28, 2023

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers)

Charenton-le-Pont, France (March 17, 2023 6:00 pm) – As of February 28, 2023, shares and voting rights outstanding of EssilorLuxottica, the global leader in the design, manufacture and distribution of ophthalmic lenses, frames and sunglasses, breaks down as indicated below.

  February 28, 2023
Shares outstanding           447,691,2391
Number of real voting rights (excluding treasury shares) 445,350,656
Theoretical number of voting rights (including treasury shares) 447,691,239

It is to be noted that voting rights are capped at 31%, applicable to any shareholder, in accordance with a formula contained in article 23 of EssilorLuxottica’s by-laws2.

For further information, please consult the Prospectus which received Visa No. 18-460 from the AMF on September 28, 2018 and its Securities Note Supplement which received Visa No. 18-494 from the AMF on October 23, 2018, available on the website www.essilorluxottica.com.

1Including 3,006 shares delivered but not yet registered as of February 28, 2023.
2EssilorLuxottica’s by-laws are available on the Company’s website under the section Governance / Publications.

Attachment

Staff

Recent Posts

Hemogenyx Pharmaceuticals PLC – Issue of Equity

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE…

3 hours ago

1933 Industries Announces Maturity of Unsecured Convertible Debentures and Encourages Conversion to Support Continued Growth

VANCOUVER, BC / ACCESS Newswire / December 18, 2025 / 1933 Industries Inc. (the "Company"…

3 hours ago

Bupa Hong Kong has selected Cognizant to deliver an AI-driven BPaaS solution to transform health insurance claims

Strategic collaboration aims to enhance operational efficiency and mitigate risks by transitioning to a business…

6 hours ago

DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count

Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE:…

12 hours ago

CranioSense Awarded $5.5 Million in Federal Grants to Validate Noninvasive Neurotech

BOSTON, Dec. 17, 2025 /PRNewswire/ -- CranioSense, Inc., a neurotechnology company developing the world's first noninvasive…

12 hours ago

Therap Services Announces 2026 National Conference Schedule: Highlighting New Tools, Best Practices, and Over 250 Specialized Sessions

TORRINGTON, Conn., Dec. 17, 2025 /PRNewswire/ -- Therap Services, the national leader in HIPAA-compliant electronic…

12 hours ago